1	Integrative polygenic risk score improves the prediction accuracy of
2	complex traits and diseases
3 4 5	Buu Truong ^{1,2} , Leland E. Hull ^{3,4} , Yunfeng Ruan ^{1,2} , Qin Qin Huang ⁵ , Whitney Hornsby ^{1,2} , Hilary Martin ⁵ , David A, van Heel ⁶ , Ying Wang ^{1,7,8} , Alicia R, Martin ^{7,8} , S, Hong Lee ⁹ , Pradeen
6 7	Natarajan ^{1,2,4}
8 9	¹ Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, 415 Main St, Cambridge, MA 02142
10 11	² Center for Genomic Medicine and Cardiovascular Research Center, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA, 02114
12 13	³ Division of General Internal Medicine, 100 Cambridge Street, Massachusetts General Hospital, Boston, MA, 02114
14 15	⁴ Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115 ⁵ Department of Human Genetics, Wellcome Sanger Institute, Cambridge, UK
16 17	⁶ Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
18 19	⁷ Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA
20 21	⁸ Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
22 23 24	⁹ Australian Centre for Precision Health, University of South Australia Cancer Research Institute, University of South Australia, Adelaide, SA, 5000, Australia
25	Please address correspondence to:
26	Pradeep Natarajan, MD MMSc
27	185 Cambridge Street, CPZN 3.184, Boston, MA 02114
28	pnatarajan@mgh.harvard.edu
29	617-726-1843
30	
31	
32	ABSTRACT
33	
34 35	outcomes of individuals. Validation and transferability of existing PPS across independent

35 id transferability of existing PRS across independent 36 datasets and diverse ancestries are limited, which hinders the practical utility and 37 exacerbates health disparities. We propose PRSmix, a framework that evaluates and 38 leverages the PRS corpus of a target trait to improve prediction accuracy, and PRSmix+, 39 which incorporates genetically correlated traits to better capture the human genetic 40 architecture. We applied PRSmix to 47 and 32 diseases/traits in European and South Asian ancestries, respectively. PRSmix demonstrated a mean prediction accuracy improvement of 41 1.20-fold (95% CI: [1.10; 1.3]; P-value = 9.17 x 10⁻⁵) and 1.19-fold (95% CI: [1.11; 1.27]; P-42 value = 1.92×10^{-6}), and PRSmix+ improved the prediction accuracy by 1.72-fold (95% CI: 43 [1.40; 2.04]; P-value = 7.58 x 10⁻⁶) and 1.42-fold (95% CI: [1.25; 1.59]; P-value = 8.01 x 10⁻⁷) 44 in European and South Asian ancestries, respectively. Compared to the previously 45 46 established cross-trait-combination method with scores from pre-defined correlated traits, we 47 demonstrated that our method can improve prediction accuracy for coronary artery disease 48 up to 3.27-fold (95% CI: [2.1; 4.44]; P-value after FDR correction = 2.6 x 10^{-4}). Our method

49 provides a comprehensive framework to benchmark and leverage the combined power of50 PRS for maximal performance in a desired target population.

51

52 INTRODUCTION

53

Thousands of polygenic risk scores (PRS) have been developed to predict an individual's genetic propensity to diverse phenotypes¹. PRS are generated when risk alleles for distinct phenotypes are weighted by their effect size estimates and summed². Risk alleles included in PRS have traditionally been identified from genome-wide association studies (GWAS) results conducted on a training dataset, which are weighted and aggregated to derive a PRS to predict distinct phenotypes. The association between PRS and the phenotype of interest is subsequently evaluated in a test dataset that is non-overlapping with the training dataset³.

61

Most PRS have been developed in specific cohorts that may vary in terms of population 62 63 demographics, admixture, environment, and SNP availability. Limited validation of many 64 PRS outside of the training datasets and poor transferability of PRS to other populations 65 may limit their clinical utility. However, pooling of data from individual PRS generated and 66 validated in diverse cohorts has the potential to improve the predictive ability of PRS across 67 diverse populations. The Polygenic Score Catalog (PGS Catalog) is a publicly available repository that archives SNP effect sizes for PRS estimation. The SNP effect sizes were 68 developed from various methods (e.g. P+T⁴, LDpred^{5,6}, PRS-CS⁷, etc.) to obtain the highest 69 prediction accuracy in the studied dataset. PRS metadata enables researchers to replicate 70 71 PRS in independent cohorts and aggregate SNP effects to refine PRS and enhance the 72 accuracy and generalizability in broader populations⁸. However, optimizing PRS 73 performance requires methodological approaches to adjust GWAS estimate effect sizes that 74 take into account correlated SNPs (i.e., linkage disequilibrium) and refine PRS for the target population^{4,5,7,9-12}. Furthermore, numerous scores are often present for single traits with 75 76 varied validation metrics in non-overlapping cohorts. There is a lack of standardized 77 approaches combining PRS from this growing corpus to enhance prediction accuracy and generalizability while minimizing bias, for a target cohort^{8,11,13}. 78

79

80 To address these issues, we sought to: 1) validate previously developed PRS in two 81 geographically and ancestrally distinct cohorts, the All of Us Research Program (AoU) and 82 the Genes & Health cohort, and 2) present and evaluate new methods for combining 83 previously calculated PRS to maximize performance beyond all best performing published 84 PRS. To better capture the genetic architecture of the outcome traits, we proposed PRSmix, 85 a framework to combine PRS from the same trait with the outcome trait. Previous studies highlighted the effect of pleiotropic information on a trait's genetic architecture^{14,15}. 86 87 Therefore, we proposed PRSmix+ to additionally combine PRS from other genetically 88 correlated traits to further improve the PRS for a given trait.

89

90 To assess the prediction improvement, we performed PRSmix and PRSmix+ for 47 traits in 91 European ancestry and 32 traits in South Asian ancestry. We evaluated 1) the relative 92 improvement of the proposed framework over the best-performing pre-existing PRS for each 93 trait, 2) the efficient training sample sizes required to improve the PRS, 3) the predictive 94 improvement in 6 groups including anthropometrics, blood counts, cancer, cardiometabolic, 95 biochemistry and other conditions as the prediction accuracies varied in each group, and 4) 96 the clinical utility and pleiotropic effect of the newly built PRS for coronary artery disease.

Overall, we show that PRSmix and PRSmix+ significantly improved prediction accuracy. An R package for preprocessing and harmonizing the SNP effects from the PGS Catalog as well as assessing and combining the scores was developed to facilitate the combining of pre-existing PRS scores for both ancestry-specific and cross-ancestry contexts using the totality of published PRS. The development of this framework has the potential to improve precision health by improving the generalizability in the application of PRS¹⁶.

- 103
- 104 **RESULTS**
- 105

106 Overview of methods

107 108



109

110 Figure 1. The framework of the trait-specific and cross-trait PRS integration. In Phase 111 1, we obtained the SNP effects from the PGS Catalog and then harmonized the effect alleles 112 as the alternative alleles in the independent cohorts. In each independent biobank (All of Us. 113 Genes & Health), we estimated the PRS and split the data into training (80%) and testing 114 (20%) datasets. In Phase 2, in the training dataset, we trained the Elastic Net model with 115 high-power scores to estimate the mixing weights for the PRSs. The training phase could 116 include PRSs from traits corresponding to outcomes (PRSmix) or all traits (PRSmix+). The 117 training was adjusted for age, sex, and 10 principal components (PCs). In Phase 3, we 118 adjusted the per-allele effect sizes from each single PRS by multiplying with the 119 corresponding mixing weights obtained in the training phase. The final per-allele effect sizes 120 are estimated as the weighted sum of the SNP effects across different single scores. In 121 Phase 4, we evaluated the re-estimated per-allele effect sizes in the testing dataset.

122

A single PRS may only reflect genetic effects captured in the discovery dataset of a single
 study that may be only a part of the total genetic effects underlying the trait of interest.
 Therefore, we harmonized and combined multiple sets of PRS to establish a new set of
 scores, which gather information across studies and traits. Our approach leveraged multiple
 well-powered PRSs to improve prediction accuracy and is detailed in Fig. 1.

128

Our combination frameworks leveraged the PGS Catalog¹⁷ as the resource of SNP effects to 129 130 estimate single PRSs. To avoid overfitting, we used All of Us and Genes & Health cohorts 131 (see Methods) due to non-overlapping samples from the original GWAS. We randomly 132 divided the target cohort into a training set (80%) and a testing set (20%). We selected the 133 most common traits from the PGS Catalog which have the highest number of PRS. For the 134 stability of the linear combination, we curated binary traits with a prevalence > 2% in the target cohort. Continuous traits were assessed using partial R² which is estimated as the 135 136 difference between the full model of PRS and covariates (age, sex, and 10 PCs) and the null 137 model of only covariates. For binary traits, the prediction accuracy was converted to liability 138 R^2 with disease prevalence approximated as the prevalence in the corresponding cohort.

139

To combine the scores, we employed Elastic Net¹⁸ to construct linear combinations of the 140 141 PRS. We proposed two combination frameworks: 1) PRSmix combines the scores 142 developed from the same outcome trait, and 2) PRSmix+ combines all the high-power 143 scores across other traits. Trait-specific combinations, PRSmix, can leverage the PRSs 144 developed from different studies and methods to more fully capture the genetic effects 145 underlying the traits. It has also been shown that complex traits are determined by genes with pleiotropic effects¹⁵. Therefore, we additionally proposed a cross-trait combination, 146 147 PRSmix+, to make use of pleiotropic effects and further improve prediction accuracy.

148

First, we evaluated the improvement for each method, defined as the fold-ratio of the method compared to the prediction accuracy of the best single PRS. For a fair comparison with the proposed framework, we selected the best single PRS from the training set and evaluated its performance in the testing set. First, we performed simulations to assess the improvement with various heritabilities and training sample sizes. We estimated the slope of improvement of prediction accuracy by increasing training sample sizes for various heritabilities.

155

156 Next, we applied the proposed frameworks in two distinct cohorts; (1) the All of Us program, 157 in which 47 traits were tested in U.S. residents of European ancestry, and (2) the Genes & 158 Health (G&H) cohort, in which 32 traits were tested in British South Asian ancestry 159 (Supplementary Table 1). In each cohort, we compared the improvement of our proposed 160 framework with the single best score from the PGS Catalog. We estimated the averaged 161 fold-ratio as a measure of the improvement of prediction accuracy by our approach, 162 compared to the best single score from PGS Catalog. We also classified the traits into 6 163 categories as anthropometrics, blood counts, cancer, cardiometabolic, biochemistry, and 164 other conditions (Supplementary Table 2 and 3). Cancer traits were not considered in the 165 younger Genes & Health cohort due to their low prevalence (<2%). We then present 166 additional detailed analyses for coronary artery disease focused on clinical utility 167 improvements relative to existing PRS.

Simulations were used to evaluate the combination frameworks

- 168
- 169
- 170





Figure 2. Simulations to demonstrate the predictive improvement of PRSmix and 173 174 **PRSmix+.** The points and triangles represent the mean fold-ratio of R² between (a) PRSmix 175 and (b) PRSmix+, respectively, versus the best single PRS. (c) The improvement per 176 logarithm with base 10 of sample size for various heritabilities was represented as a slope of 177 a linear regression of fold-ratio $\sim \log 10(N)$. In simulations, the correlation within simulated 178 trait-specific PRSs was 0.8, and the correlation between trait-specific and correlated PRSs 179 was 0.4 (see Methods). The whiskers demonstrate confidence intervals across 200 180 replications. The dashed red lines represent the reference for fold-ratio equal 1 for (a) and 181 (b), and equal 0 for (c).

182

183 To compare the performance of PRSmix and PRSmix+ against the best single PRS and 184 evaluate the sample sizes needed for training the mixing weights, we performed simulations 185 with real genotypes of European ancestry in the UK Biobank given the large sample sizes 186 available (Fig. 2). Briefly, we randomly split 7,000 individuals as a testing data set mimicking 187 the testing size of 20% of real data. In the remaining dataset, we used 200,000 individuals 188 for GWAS to estimate the SNP effect sizes for PRS calculations. Finally, with the rest of the 189 data, we randomly selected different sample sizes as the training sample to evaluate the 190 sample sizes needed to train the mixing weights. To assess the improvement of PRS 191 performance, we computed the fold-ratio of prediction accuracy R² between PRSmix and 192 PRSmix+ against the best-performing single simulated PRS.

193

194 Our results showed that the trait-specific combination, PRSmix, showed no improvement 195 with the training sample smaller than 500 for most of the traits. Our simulations illustrated 196 that traits with low heritability required a larger sample size to achieve an improvement 197 compared to traits with high heritability (Fig. 2a and 2b). PRSmix demonstrated a better performance compared to the best single PRS with training sample sizes from N_{training} = 200 198 samples for the high heritable trait ($h^2 = 0.4$) to $N_{\text{training}} = 5000$ samples for the low heritable 199 trait (h²=0.05) (Fig. 2a and 2b). We observed that PRSmix demonstrated a saturation of 200 201 improvement from N_{training} = 10,000. PRSmix+ demonstrated negligible further improvement 202 when the training sample size was increased from 30,000 but maintained consistent 203 improvement relative to PRSmix and the best single PRS. Moreover, we observed that traits 204 with higher heritability or higher best prediction accuracy of a single PRS demonstrated a 205 smaller improvement compared to traits with a smaller heritability (Fig. 2c).





213 Figure 3. Comparison of PRSmix and PRSmix+ versus the best PGS Catalog in 214 European and South Asian ancestries. The relative improvement compared to the best 215 single PRS was assessed in (a) the European ancestry in the All of US cohort and (b) South 216 Asian ancestry in the Genes & Health cohort. PRSmix combines trait-specific PRSs and 217 PRSmix+ combines additional PRSs from other traits. The best PGS Catalog score was 218 selected by the best performance trait-specific score in the training sample and evaluated in the testing sample. The prediction accuracy (R^2) was calculated as partial R^2 which is a 219 difference of R² between the model with PRS and covariates including age, sex, and 10 PCs 220 221 versus the base model with only covariates. Prediction accuracy for binary traits was 222 assessed with liability-R² where disease prevalence was approximately estimated as a 223 proportion of cases in the testing set. The whiskers reflect the maximum and minimum 224 values within the 1.5 x interquartile range. The bars represent the ratio of prediction 225 accuracy of PRSmix and PRSmix+ versus the best PRS from the PGS Catalog across 47 226 traits and 32 traits in All of Us and Genes and Heath cohorts, respectively, and the whiskers 227 demonstrate 95% confidence intervals. P-values for significance difference of the fold-ratio 228 from 1 using a two-tailed paired t-test. PRS: Polygenic risk scores.

229

230 To determine if a trait-specific combination, namely PRSmix, would improve the accuracy of 231 PRS prediction, we used data from European ancestry participants in the All of Us research 232 program who had undergone whole genome sequencing, and Genes & Health participants 233 of South Asian ancestry. We randomly split the independent cohorts into training (80%) and 234 testing sets (20%). The training set was used to train the weights of each PRS, referred as 235 mixing weights, that indicate how much each PRS explain the phenotypic variance in the 236 training set, and the PRS accuracies were evaluated in the testing set (Fig. 1). We curated 237 47 traits and 32 traits in the All of Us and Genes & Health cohorts, respectively. For binary 238 traits, we removed traits with a prevalence of smaller than 2% (see Methods, Supplementary

Table 1). Traits with the best-performance trait-specific single PRS which showed a lack of power were also removed. Overall, we observed a significant improvement compared to 1 using a two-tailed paired t-test with PRSmix. PRSmix significantly improves the prediction accuracy compared to the best PRS estimated from the PGS Catalog. PRSmix improved 1.20-fold (95% CI: [1.10; 1.3]; P-value = 9.17 x 10⁻⁵) and 1.19-fold (95% CI: [1.11; 1.27]; Pvalue = 1.92 x 10⁻⁶) compared to the best PRS from PGS Catalog for European ancestry and South Asian ancestry, respectively.

246

In European ancestry, we observed the greatest improvement of PRSmix against the best single PRS for rheumatoid arthritis of 3.36-fold. Furthermore, in South Asian ancestry, we observed that PRSmix of coronary artery disease had the best improvement of 2.32-fold compared to the best-performance single PRS. Details of the prediction accuracy are shown in Supplementary Fig. 1, 2 and Supplementary Table 2, 3. This was consistent with findings in simulations since traits with a lower single PRS performance demonstrated a better improvement with the combination strategy.

254

255 **Cross-trait combination further improved PRS accuracy and highlighted the** 256 **contribution of pleiotropic effects (PRSmix+)**

257

258 We next assessed the contribution of pleiotropic effects from cross-trait PRSs to determine if 259 these would further improve the combination framework (PRSmix+), by including high-power 260 PRSs from within 2600 PRSs in the PGS Catalog. To evaluate the power of PRS and 261 improve computational efficiency, we employed the theoretic power and variance of partial R^2 for continuous traits and liability R^2 for binary traits (see Methods). We observed that 262 263 PRSmix+ further improved the prediction accuracy compared to the best PGS Catalog in 264 European ancestry (Fig. 3a) and South Asian ancestry (Fig. 3b). We observed an improvement of 1.72-fold (95% CI: [1.40; 2.04]; P-value = 7.58 x 10⁻⁶) and 1.42-fold (95% CI: 265 266 [1.25; 1.59]; P-value = 8.01 x 10^{-7}) higher compared to the best PGS Catalog for European 267 ancestry and South Asian ancestry, respectively. PRSmix+ significantly improved the 268 prediction accuracy compared to PRSmix, in both European and South Asian ancestry with 269 1.46-fold (95% CI: [1.17; 1.75]; P-value = 0.002) and 1.19-fold (95% CI: [1.07; 1.32]; P-value 270 = 0.001), respectively (Supplementary Fig. 3).

271

Consistent with our simulation results, a smaller improvement was observed for traits with a
higher baseline prediction accuracy from PGS Catalog (Supplementary Fig. 4), noting that
the baseline prediction accuracy depends on the heritability and genetic architecture (i.e.
polygenicity). In contrast, more improvement was observed for traits with lower heritability,
thus lower prediction accuracy, when comparing the single best PRS (Fig. 1c).

277

278 Prediction accuracy and predictive improvement across various types of traits

279





282 Figure 4. Prediction accuracy and improvement across various types of traits in the 283 European and South Asian ancestry. We classified the traits into 6 main categories for 284 European ancestry in the All of Us cohort and 5 categories for South Asian ancestry in the 285 Genes & Health cohort due to the low prevalence of cancer traits in Genes & Health. The 286 prediction accuracies, (a) and (c), are estimated as partial R^2 and liability R^2 for continuous 287 traits and binary traits, respectively. The relative improvements, (b) and (d), are estimated as 288 the fold-ratio between the prediction accuracies of PRSmix and PRSmix+ against the best 289 PGS Catalog. The order on the axis followed the decrease in the prediction accuracy of 290 PRSmix+. The boxplots in (a) and (c) show the first to the third quartile of prediction 291 accuracies for 47 traits and 32 traits in European and South Asian ancestries, respectively. 292 The whiskers reflect the maximum and minimum values within the 1.5 x interguartile range

293 for each group. The bars in (b) and (d) represent the mean prediction accuracy across the 294 traits in that group and the whiskers demonstrate 95% confidence intervals. The red dashed 295 line in (b) and (d) represents the ratio equal to 1 as a reference for comparison with the best 296 PGS Catalog score. The asterisk (*) and (**) indicate P-value < 0.05 and P-value < 0.05 / 297 number of traits in each type with a two-tailed paired t-test, respectively.

299 We next compared PRSmix and PRSmix+ with the best PRS estimated from the PGS 300 across 6 categories, including anthropometrics, blood counts, cancer, Catalog 301 cardiometabolic, biochemistry, and other conditions (see Methods). PRSmix demonstrates a 302 higher prediction accuracy across all types of traits in both European and South Asian 303 ancestries (Fig. 4). We observed a similar trend in the predictive performance of PRSmix+ 304 across different types of traits. In European, the smallest improvement with PRSmix+ was in 305 anthropometric traits of 1.14-fold (95% CI: [1.03; 1.25]; P-value = 0.01) while "other 306 conditions" (including depression, asthma, migraine, current smoker, hypothyroid, 307 osteoporosis, glaucoma, rheumatoid arthritis, and gout) obtained the highest mean 308 predictive improvement but also with high variance of 2.66-fold (95% CI: [1.30; 4.01]; P-309 value = 0.01) (Supplementary Table 4). In South Asian ancestry, the mean predictive 310 improvement was highest in "other conditions" (including asthma, migraine, current smoker, 311 and rheumatoid arthritis) type of 2.10-fold (95% CI: [0.787; 3.405]; P-value = 0.1). 312 Biochemistry demonstrated the smallest improvement of 1.23-fold (95% CI: [1.15; 1.31]; Pvalue = 5.8 x 10⁻⁹). We note that PRSmix and PRSmix+ improve prediction accuracy for all 313 314 traits (Supplementary Table 2 and 3). The large variance could be due to the wide range of 315 improvement and the small number of traits in each subtype.

316

298

317 Comparison with previous combination methods

318



319

Figure 5. Benchmarking previous methods with PRSmix and PRSmix+. LDpred2-auto 320 321 was used as the baseline method to input in the methods. 5 traits from Maier et al.¹⁹ and 26 publicly available GWAS for European ancestry were curated. The components of each 322 323 combination method are denoted in parentheses. wMT-SBLUP was conducted with the input 324 of sample sizes from the GWAS summary statistics and heritabilities and genetic correlation

325 between all pairs of traits using LD score regression. PRSmix (LDpred2 + PGS Catalog) 326 combined target trait-specific scores within 26 scores and PGS Catalog. Elastic Net 327 (LDpred2) was performed using Elastic Net with all scores from 26 traits generated with 328 LDpred2-auto. PRSmix+ (LDpred2 + PGS Catalog) was conducted using 26 scores from 329 LDpred2-auto and scores from all traits obtained from PGS Catalog. Partial R2 and liability 330 R2 were used for continuous traits and binary traits, respectively. The whiskers demonstrate 331 95% confidence intervals of mean prediction accuracy. BMI, Body mass index; CAD, 332 coronary artery disease; T2D, type 2 diabetes. GWAS, genome-wide association study.

333

334 There have been several studies proposed to incorporate multiple traits to improve prediction accuracy of the target trait^{8,19,20}. For example, wMT-SBLUP¹⁹ created a weighted 335 index for correlated PRSs and required the input sample sizes, genetic correlation and 336 337 heritability across all pairs of traits from GWAS summary statistics to be determined. Krapohl et al.²⁰ and Albinana et al.¹³ combined PRSs using scores estimated from LDpred2⁵. Here 338 we benchmarked PRSmix and PRSmix+ against the previous methods using summary 339 340 statistics with a pre-defined set of correlated traits to the main outcomes and an extension of 341 scores generated by different methods from PGS Catalog (Fig. 5).

342

343 We first observed that integrating scores by Elastic Net with scores from pre-defined traits 344 improved prediction accuracy compared to wMT-SBLUP ranging between 1.08-fold (95% CI: 345 [1.03; 1.12]; P-value after FDR correction = 0.36) for T2D and 2.87-fold (95% CI: [1.58; 346 4.15]; P-value = 0.006) for CAD (Supplementary Table 5 and Supplementary Table 6). 347 PRSmix+, with scores from both pre-defined traits and PGS Catalog, demonstrated a 348 consistent boost in prediction accuracy compared to wMT-SBLUP between 1.12-fold (95% 349 Cl: [1.02; 1.21]; P-value = 0.016) for T2D and 3.27-fold (95% Cl: [2.1; 4.44]; P-value = 2.6 x 350 10⁻⁴) for CAD. PRSmix+ equipped with both LDpred2-auto and PGS Catalog scores also 351 outperformed the Elastic Net combination of LDpred2 scores best observed with 1.6-fold 352 $(95\% \text{ Cl: } [1.31; 1.89]; \text{ P-value} = 1.1 \times 10^{-4})$ for depression. Interestingly, height, a highly 353 polygenic trait²¹, demonstrated has the similarly best performance under a trait-specific combination (PRSmix with trait-specific LDpred2-auto and PGS Catalog scores) and 354 355 PRSmix+ equipped with both LDpred2-auto and PGS Catalog scores (Fig. 5). Employing 356 pleiotropic effects only provided a small improvement with height (Supplementary Table 6). 357 On the other hand, T2D demonstrated that all methods of cross-trait combinations provided 358 a significant improvement over the trait-specific combination (Fig. 5).

- 359
- 360 Clinical utility for coronary artery disease
- 361
- 362





372

Figure 6. Comparison of prediction accuracies with PRSmix, PRSmix+ and CAD PRS from PGS Catalog. PRSmix was computed as a linear combination of CAD PRS and PRSmix+ was computed as a linear combination of all significant PRS obtained from the PGS Catalog. The PRSs were evaluated in the testing set with liability R² in the (a) European ancestry from the All of Us cohort and b) South Asian ancestry from the Genes & Health cohort. The bars indicate the mean prediction accuracy and the whiskers show 95% confidence intervals. CAD, coronary artery disease.



Figure 7. Net reclassification improvement (NRI) for coronary artery disease with the
 addition of polygenic risk scores to the baseline model in European and South Asian
 ancestries. The baseline model for risk prediction includes age, sex, total cholesterol, HDL C, systolic blood pressure, BMI, type 2 diabetes, and current smoking status. We compared
 the integrative models with PGS Catalog, PRSmix, and PRSmix+ in addition to clinical risk

factors versus the baseline model with only factors. The points indicate the mean estimate
for continuous NRI and the whiskers indicate 95% confidence intervals estimated from 500
bootstraps. HDL-C: High-density lipoprotein; BMI: Body mass index. NRI: Net
Reclassification Improvement.

382

383

384 To evaluate the utility of the proposed methods, we assessed the PRSmix and PRSmix+ for 385 coronary artery disease (CAD), which is the leading cause of disability and premature death among adults²²⁻²⁴. The single best CAD PRSs (PRS_{CAD}) s from the PGS Catalog in the 386 training set were from Koyama S. et al²⁵. and Tamlander M. et al.²⁶ in European and South 387 388 Asian ancestries, respectively (Supplementary Fig. 5 and Supplementary Fig. 6). In the 389 testing set, liability R² with Koyama S et al. for European ancestry was 0.03 (95% CI: [0.03; 0.04]; P-value < 2 x 10^{-16}) and with Tamlander M. et al. for South Asian ancestry was 0.006 390 $(95\% \text{ CI: } [0.003; 0.009]; \text{ P-value} = 2.39 \times 10^{-4})$ (Fig. 6). 391

392

393 Subsequently, we assessed the clinical utility of the integrative model with PRS and 394 established clinical risk factors, including age, sex, total cholesterol, HDL-C, systolic blood 395 pressure, BMI, type 2 diabetes, current smoking status versus the traditional model with 396 clinical risk factors. (Fig. 7 and Supplementary Table 7). In European ancestry, the CAD 397 PRSmix+ integrative score improved the continuous net reclassification of 35% (95% CI: [26%; 45%]; P-value < 2 x 10⁻¹⁶) compared to PRSmix (30%; 95% CI: [21%; 38%]; P-value = 398 P-value $< 2 \times 10^{-16}$) and the best PRS from the PGS Catalog (28%; 95% CI: [19%; 38%]; P-399 value < 2 x 10^{-16}). In South Asian ancestry, the integrated score with PRSmix+ showed 400 401 significant continuous net reclassification of 27% (95% CI: [16%; 38%]; P-value = 6.07 x 10⁻ 402 ⁷) compared to PRSmix (15%; 95% CI: [9%; 20%]; P-value = 7.18 x 10^{-6}) and the best PGS 403 Catalog (7%; 95% CI: [1%; 13%]; P-value = 0.02). Our results also demonstrated an 404 improvement in net reclassification for models without clinical risk factors (Supplementary 405 Table 7).

406

407 We assessed the incremental area under the curve (AUC) between the full model of PRS 408 and covariates and the null model with only covariates (Supplementary Table 8). PRSmix+ 409 demonstrated an incremental AUC of 0.02 (95% CI: [0.018; 0.02]; P-value < 2.2x10⁻¹⁶) and 0.008 (95% CI: [0.007; 0.009]; P-value<2.2x10⁻¹⁶) in European and South Asian ancestries, 410 411 respectively. PRSmix obtained an incremental AUC of 0.016 (95% CI: [0.016; 0.017]; Pvalue < 2.2x10⁻¹⁶) and 0.006 (95% CI: [0.005; 0.007]; P-value < 2.2x10⁻¹⁶) in European and 412 413 South Asian ancestries, respectively. The best PGS Catalog had the smallest incremental 414 AUC of 0.012 (95% CI: [0.011; 0.013]; P-value<2.2x10⁻¹⁶) and 0.003 (95% CI: [0.002; 0.003]; 415 P-value $< 2.2 \times 10^{-16}$) in European and South Asian ancestries, respectively.

416

417 We also compared the risks for individuals in the top decile versus the remaining population 418 (Supplementary Table 9). For European ancestry, an increased risk with OR per 1-SD of the 419 best PGS Catalog, PRSmix and PRSmix+ were 1.43 (95% CI: [1.30-1.57]; P-value < 2.2x10 ¹⁶), 1.60 (95% CI: [1.45-1.76]; P-value < 2.2×10^{-16}) and 1.74 (95% CI = [1.58; 1.91]; P-value 420 $< 2.2 \times 10^{-16}$), respectively. The top decile of PRSmix+ compared to the remaining population 421 422 demonstrated an increased risk of OR = 2.53 (95% CI: [1.96; 3.25]; P-value =8.64 x 10⁻¹³). 423 The top decile for the best PGS Catalog versus the remainder was OR = 1.67 (95% CI: 424 [1.27; 2.19]; P-value = 2 x 10⁻⁴). For South Asian ancestry, an increased risk with OR per 1-425 SD of the best PGS Catalog, PRSmix and PRSmix+ was 1.24 (95% CI: [1.13; 1.37]; P-value

426 < 1.52×10^{-16}), 1.39 (95% CI: [1.33; 1.46]; P-value < 2.2×10^{-16}), 1.40 (95% CI: [1.27; 1.55]; 427 P-value < 2.2×10^{-16}) and 1.50 (95% CI = [1.36; 1.66]; P-value < 2.2×10^{-16}), respectively. In 428 South Asian ancestry, PRSmix+ demonstrated an OR of 2.34 (95% CI: [1.79; 3.05]; P-value 429 = 4.22×10^{-10}), and with the best PGS Catalog, OR was 1.73 (95% CI: [1.30; 2.28]; P-value 430 = 1.31×10^{-4}) for the top decile versus the remaining population.

431

432 Moreover, we observed that there is a plateau of improvement for PRSmix from the training 433 size of 5000 in both European and South Asian ancestries (Supplementary Fig. 7), which 434 aligned with our simulations (Fig. 2a and 2b). Our results demonstrated the generalization of 435 our combination methods across diverse ancestries to improve prediction accuracy. With 436 PRSmix+, our empirical result showed that there was a modest improvement with training 437 sample sizes larger than 5,000.

438

Finally, we conducted phenome-wide association studies (PheWAS) in All of Us between 439 440 PRS_{CAD} with 1815 phecodes to compare the pleiotropy of PRS and assess the relationship 441 between CAD PRS and disease phenotypes given the inherent use of pleiotropy in 442 development (Supplementary Table 10). As expected, PRSmix+ had a stronger association 443 for coronary atherosclerosis relative to the single best PRS from the PGS Catalog. PRSmix+ 444 associations with cardiometabolic risk factors were significantly greater with averaged foldratio = 1.10 (95% CI: [1.09-1.12]; P-value with paired T test =1.07 x 10⁻²⁵) and 1.07 (95% CI: 445 [1.05-1.081]; P-value = 4.8×10^{-13}) for circulatory system and endocrine/metabolic system 446 447 (Supplementary Table 11). The PheWAS result for PRSmix+ aligned with the list of traits 448 from the selected PRS (Supplementary Table 10).

449

450 **DISCUSSION**

451

452 In this paper, we propose a trait-specific framework (PRSmix), and cross-trait framework 453 (PRSmix+) to leverage the combined power of existing scores. We performed and evaluated 454 our method using the All of Us and Genes & Health cohorts showcasing a framework to 455 develop the most optimal PRS for a given trait in a target population leveraging all existing 456 PRS. Across 47 traits in All of Us cohort and 32 traits in the Genes & Health cohort with 457 either continuous traits or binary traits with prevalence > 2%, we demonstrated substantial improvement in average prediction R² by using a linear combination with Elastic Net. The 458 459 empiric observations are concordant with simulations. To our knowledge, there has been a 460 number of emerging studies to combine PRS, but there is a limited number of frameworks 461 that comprehensively evaluate, harmonize, and leverage the combination of these 462 scores^{8,13,27}. Our studies permit several conclusions for the development, implementation, 463 and transferability of PRS.

464

First, externally derived and validated PRS are generally not the most optimal PRS for a given cohort. Consistent with other risk predictors, recalibration within the ultimate target population improves performance²⁸. By leveraging the PGS Catalog, our work carefully harmonizes the risk alleles to estimate PRS across all scores and provides newly estimated per-allele SNP effects (provided to the PGS Catalog) to assist the interpretability of the models.

471

472 Second, previous studies selected an arbitrary training sample size to estimate the mixing 473 weights, which may lead to a poor power of the combination frameworks and inaccurate

474 estimate of sampling variance¹⁰. We assessed the expected sample sizes to estimate the
475 mixing weights via simulations and real data. Our results demonstrated that while low
476 heritability traits benefit the most, they require a greater training sample size.

477

Third, we leveraged all PRS, including those not trained on the primary trait, to systematically optimize PRS for a target cohort. We showed that PRSmix improved the prediction by combining the scores matching the outcome trait. In addition, we showed that PRSmix+ was able to leverage the power of cross-traits, which highlighted the contribution of pleiotropic effects to enhance PRS performance. We leverage prior work demonstrating the effects of pleiotropy on complex traits^{15,29,30}.

484

485 Fourth, we demonstrated that our method outperformed previous methods combining scores. We showed that PRSmix+ outperformed wMT-SBLUP¹⁹ using a limited number of 486 correlated traits. wMT-SBLUP required GWAS's sample sizes, heritability, and genetic 487 488 correlation between all traits. LDpred2-auto required GWAS summary statistics and initialized heritability and proportion of causal SNPs. Krapohl et al.²⁰ and Abraham et al.⁸ 489 490 proposed to use Elastic Net to combine the scores developed from summary statistics, and 491 correlated traits were selected with prior knowledge. However, these strategies consider 492 scores developed from a particular methods using predefined summary statistics. Our 493 framework utilizes all PRSs available in the PGS Catalog which were optimized for their 494 target traits. Additional summary statistics and PRS scores could be added to further 495 enhance the models. We let our Elastic Net model penalize the component PRSs without the 496 need for prior knowledge. Elastic Net can select PRSs to include and efficiently handle multicollinearity^{31–33}. Furthermore, PRSmix and PRSmix+ only required a set of SNPs effect to 497 498 estimate the PRSs and estimated the prediction accuracy to the target trait to select the best 499 scores for the combination. Additionally, compared to the preselected traits for stroke by Abraham et al.⁸ we also observed that our method could identify more related risk factors to 500 501 include compared to previous work conducted on stroke (Supplementary Fig. 8). Therefore, 502 our method is more comprehensive in an unbiased way in terms of choosing the risk factors 503 and traits to include with empirically improved performance.

504

505 Fifth, greater performance is observed even for non-European ancestry groups 506 underrepresented in GWAS and PRS studies. We empirically demonstrate the value of 507 training and incorporating pleiotropy with all available PRS to improve performance, 508 including multiple metrics of clinical utility for CAD prediction in multiple ancestries. In South 509 Asian ancestry, we observed that PRSmix and PRSmix+ demonstrated a significant 510 improvement with the best improvement for CAD. Of note for CAD, the relative 511 improvements in South Asian ancestry were higher than in European ancestry for PRSmix 512 and equivalent for PRSmix+. Transferability of PRS has been shown to improve the clinical utility of PRS in non-European ancestry^{16,34}. Although the prediction accuracy for South 513 514 Asian ancestry is still limited, our results highlighted the transferability of predictive 515 improvement with PRSmix and PRSmix+ to South Asian ancestry. We anticipate that 516 ongoing and future efforts to improve our understanding of the genetic architecture in non-517 European ancestries will further improve the transferability of PRS across ancestry.

518

Lastly, traits with low heritability or generally low-performing single PRS benefit the most from this approach, especially with PRSmix+, such as migraine in both European and South Asian ancestries. Additionally, our results showed that pleiotropic effects play an important

522 role in understanding and improving prediction accuracies of complex traits. However, 523 anthropometric traits, which are highly polygenic³⁵ and have good predictive performance 524 using the best PGS Catalog, also showed improvement with the combination framework in 525 both European and South Asian ancestries.

526

527 Given that PRSmix+ outperformed PRSmix, one might consider if there is a reason to use 528 PRSmix instead of PRSmix+. We observed that in cases of highly heritable traits or high 529 performance with a single PRS, there was only marginal improvement of PRSmix+ over 530 PRSmix. In this scenario, PRSmix could provide similar predictive performance while being 531 less time-consuming because trait-specific PRS inputs only are required. However, for traits 532 with lower heritability PRSmix+ shows a marked improvement over PRSmix and would be preferred. Wang et al.³⁶ showed that the theoretical prediction accuracy of the target trait 533 using the PRS from the correlated trait is a function of genetic correlation, heritability, 534 535 number of genetic variants and sample size. Future directions could include defining the 536 minimum parameters required for the performance of the PRSmix+ model to improve on 537 single trait-specific PRS.

538 539 Our work has several limitations. First, the majority of scores from PGS Catalog were 540 developed in European ancestry populations. Further non-European SNP effects will likely 541 improve the single PRS power, which may in turn, also improve the prediction accuracy of 542 our proposed methods. Second, the Elastic Net makes a strong assumption that the 543 outcome trait depends on a linear association with the PRS and covariates. However, a 544 recent study demonstrated there is no statistical significance difference between linear and non-linear combinations for neuropsychiatric disease¹³. Third, we did not validate the mixing 545 546 weights in an independent cohort. We expect that in the future, there will be emerging large 547 independent biobanks, but prior non-genetic work demonstrates the value of internal 548 calibration for optimal risk prediction. Fourth, we estimated the mixing weights for each 549 single SNP as a mixing weight of the PRS. Future studies could consider linkage 550 disequilibrium between the SNPs and functional annotations of each SNP. Fifth, our 551 frameworks were conducted on binary traits with a prevalence > 2%. Additional combination 552 PRS models are emerging that seek to use preexisting genotypic data from genetically 553 related, but low prevalence conditions, to improve the prediction accuracy of rare 554 conditions¹³. Sixth, the baseline demographic characteristics (i.e., age, sex, social economic 555 status) in the target cohort might limit the validation and transferability of PRS³⁷. Although 556 these factors were considered by using a subset of the target cohorts as training data, it is 557 necessary to have PRS developed on similar baseline characteristics. Lastly, with the 558 expanding of all biobanks, there might be no perfect distinction between the samples 559 deriving PRS and the testing cohort, future studies may consider the potential intersection 560 samples to train the linear combination. 561

562 In conclusion, our framework demonstrates that leveraging different PRS either trait-specific 563 or cross-trait can substantially improve model stability and prediction accuracy beyond all 564 existing PRS for a target population. Importantly, we provide software to achieve this goal in 565 independent cohorts.

- 567 **METHODS**
- 568

566

569 Data

- 570 571 The All of Us Research Program
- 572

573 The All of Us Research Program is a longitudinal cohort continuously enrolling (starting May 574 2017) U.S. adults ages 18 years and older from across the United States, with an emphasis 575 on promoting inclusion of diverse populations traditionally underrepresented in biomedical 576 research, including gender and sexual minorities, racial and ethnic minorities, and participants with low levels of income and educational attainment.³⁸ Participants in the 577 program can opt-in to providing self-reported data, linking electronic health record data, and 578 providing physical measurement and biospecimen data.³⁹ Details about the All of Us study 579 580 goals and protocols, including survey instrument development,⁴⁰ participant recruitment, data collection, and data linkage and curation were previously described in detail.^{39,41} 581

582

Data can be accessed through the secure All of Us Researcher Workbench platform, which 583 is a cloud-based analytic platform that was built on the Terra platform.⁴² Researchers gain 584 access to the platform after they complete a 3-step process including registration, 585 586 completion of ethics training, and attesting to a data use agreement attestation.⁴³ All of Us 587 uses a tiered approach based on what genomic data is accessible through the Controlled 588 Tier, and includes both whole genome sequencing (WGS), genotyping array variant data in 589 multiple formats, as well as variant annotations, access to computed ancestry, and quality 590 reports.⁴⁴ This study includes data on the 98,600 participants with (WGS) data in the All of 591 Us v6 Curated Data Repository release. Participant data in this data release was collected 592 between May 6, 2018 and April 1, 2021. This project is registered in the All of Us program 593 under the workspace name "Polygenic risk score across diverse ancestries and biobanks."

- 594
- 595 The Genes & Health Biobank
- 596

597 Genes & Health is a community-based genetics study enrolling British South Asian, with an 598 emphasis on British Bangladeshi (two-thirds) and British Pakistani (remaining) people, with a 599 goal of recruiting at least 100,000 participants. Currently, over 52,000 participants have 600 enrolled since 2015. All participants have consented for lifelong electronic health record 601 access and genetic analysis. The study was approved by the London South East National 602 Research Ethics Service Committee of the Health Research Authority. 97.4% of participants 603 in Genes & Health are in the lowest two guintiles of the Index of Multiple Deprivation in the 604 United Kingdom. The cohort is broadly representative of the background population with 605 regard to age, but slightly over-sampled with females and those with medical problems since 606 two-thirds of people were recruited in healthcare settings such as General Practitioner 607 surgeries⁴⁵.

- 608
- 609 The Polygenic Score (PGS) Catalog
- 610

Polygenic risk scores were obtained from the Polygenic Score (PGS) Catalog¹⁷, which is a 611 612 publicly accessible resource cataloging published PRS, including the metadata. The 613 metadata provides information describing the computational algorithms used to generate the 614 score, and performance metrics to evaluate a PRS¹⁷. At the time of this study, over 2,600 615 PRS were cataloged in the PGS Catalog (version July 18, 2022) designed to predict 538 616 distinct traits.

617

618 Clinical Outcomes

619

620 Clinical phenotypes were curated using a combination of electronic health record data, direct 621 physical measurements, and/or self-reported personal medical history data, from the *All of* 622 *Us* v6 Data Release as detailed in Supplementary Table 16. Individuals in the Genes and 623 Health cohort were also curated with similar definitions based on ICD10, SNOMED and 624 operation codes (Supplementary Table 17). Traits with the best performing single trait-625 specific PRS with power < 0.95 such as hemoglobin, sleep apnea, and depression were 626 removed. Binary traits with a prevalence < 2% were removed.

627

628 A linear combination of scores

629

630 We proposed PRSmix to combine PRS of outcome traits and PRSmix+ to combine high-631 power PRS (defined in the following subsection) from all traits obtained from PGS Catalog. 632 The linear combination was conducted by using an Elastic Net algorithm from the "glmnet" R package46 (version 4.1) to combine the estimated PRS. First, we randomly split the 633 634 independent cohorts into 80% of training and 20% testing. The PRS in the training set was 635 standardized with mean 0 and variance 1. Before conducting linear combination, we first 636 evaluated the performance of each individual PRS by their power and P-value (see below). 637 An Elastic Net algorithm was used with 5-fold cross-validation and default parameters to 638 estimate the mixing weights of each PRS. The mixing weights were then divided by the 639 corresponding original standard deviation of the PRS in the training set. 640

640

$$\hat{\alpha}_i = \hat{\omega}_i / \sigma_i$$

641

642 Where $\hat{\omega}_i$ and σ_i is the mixing weight estimated from the Elastic Net and standard deviation 643 of PRS_i in the training set, respectively. $\hat{\alpha}_i$ is the adjusted mixing weight for PRS_i. To derive 644 the per-allele effect sizes from the combination framework, we multiplied the SNP effects 645 with the corresponding adjusted mixing weights:

$$\hat{\gamma}_j = \sum_{i=1}^M \hat{\alpha}_i * \beta_j$$

646 Where $\hat{\gamma}_i$ is the adjusted effect size of SNP_j and β_{ij} is the original effect sizes of SNP_j in 647 PRS_i. We set $\beta_{ji} = 0$ if SNP_j is not in PRS_i. The adjusted effect sizes were then utilized to 648 calculate the final PRS.

649

The mixing weights for PGS Catalog scores for PRSmix and PRSmix+ in European ancestry are provided in Supplementary Table 12 and Supplementary Table 13, respectively. For South Asian ancestry, the mixing weights for PRSmix and PRSmix+ in European ancestry are provided in Supplementary Table 14 and Supplementary Table 15, respectively.

654

656

655 Power and variance of PRS accuracy

657 We selected high-power PRS to conduct the combination by assessing the power and 658 variance of prediction accuracy. The power of PRS can be estimated based on the power of 659 the two-tailed test of association as follow^{3,47}:

660

661
$$1 - \phi(\phi^{-1}(1 - \alpha/2) - \sqrt{\lambda}) + \phi(\phi^{-1}(\alpha/2) - \sqrt{\lambda})$$
(1)

 $\lambda = \frac{NR^2}{1-R^2} \quad (2)$

662 663 where ϕ is the Chi-squared distribution function, α is the significance level, and λ is the non-664 centrality parameter which can be estimated as

665

666 667

668 where N, R^2 is the sample size and estimated prediction accuracy in the testing set, 669 respectively. R^2 can be estimated as partial R^2 or liability R^2 for continuous traits and binary 670 traits, respectively. Briefly, partial R^2 compared the difference in goodness-of-fit between a 671 full model with PRS and covariates including age, sex, and first 10 PCs, and a null model 672 with only covariates. Additionally, for binary traits, liability R^2 was estimated with the disease 673 prevalence approximated as the prevalence in the samples. The theoretical variance and 674 standard error of R^2 can be estimated as follow^{48–50}:

675 676

677

Therefore, we can analytically estimate the confidence interval of prediction accuracy for each of the score. We selected high-power scores defined as power > 0.95 with P-value <= 0.05 or P-value <= 1.9 x 10⁻⁵ (0.05/2600) for the combination with Elastic Net.

 $se(R^2) = \sqrt{var(R^2)} = \sqrt{\frac{4R^2(1-R^2)(N-2)^2}{(N^2-1)(N+3)}}$ (3)

681

685

687

To compare the improvement, for instance between PRSmix and the best PGS Catalog, we estimate the mean fold-ratio of R^2 across different traits with its 95% confidence interval and evaluated the significance difference from 1 using a two-tailed paired t-test.

686 Simulations

688 We used UK Biobank European ancestry to conduct simulations for trait-specific and cross-689 trait combinations. Overall, we simulated 7 traits with heritability h^2 equal to 0.05, 0.1, 0.2, and 0.5. We randomly selected M=1000 causal SNPs among 1.1 million HapMap3 variants 690 with INFO > 0.6, MAF > 0.01 and P-value Hardy-Weinberg equilibrium > 10^{-7} . We removed 691 692 individuals with PC1 and PC2 > 3 standard deviation from the mean. We randomly remove 693 one in a pair of related individuals with closer than 2nd degree. The genetic components 694 were simulated as PRSs where PRS1, PRS2, and PRS3 are considered trait-specific scores 695 with genetic correlations are 0.8 and 0.4 for cross-trait scores. PRS4, PRS5 and PRS6 are 696 simulated as pleiotropic effects on the outcome traits with genetic correlation equal to 0.4. 697 The SNP effects for PRSs are simulated by a multivariate normal distribution $MVN(0, \Sigma)$ 698 where Σ is the covariance matrix between PRSs. The main diagonal contains the heritability of the traits as h^2 / M and the covariance between PRSs are simulated as $r_a * h^2$ / M where 699 r_a is the genetic correlation between PRSs (0.8 for trait-specific scores and 0.4 for cross-trait 700 701 scores). The PRSs of the outcome are estimated by the weighted combination of PRS where 702 the weights follow U(0,1). 7 phenotypes were simulated as $y = g + e_1 e \sim N(0, 1 - h^2)$ where 703 g is PRS and e is the residuals.

704

We split the simulated cohort into 3 data sets for: 1) GWAS 2) training set: training the mixing weights with a linear combination and 3) testing set: testing the combined PRS. We incorporated PRS1, PRS2 and PRS3 to assess the trait-specific PRSmix framework. We

combined all 6 single PRS to evaluate the cross-trait PRSmix+ framework. We compared the fold-ratio of the R² of the combined PRS to the R² of best single PRS to assess the improvement of the combination strategy. To evaluate the improvement across different heritabilities, we estimated the slope of improvement per log10(N) increase of training sample sizes on the fold-ratio of predictive improvement.

713

714 Sample and genotyping quality control

715

716 The AoU data version 5 contains more than 700 million variants from whole genome 717 sequencing³⁹. We curated European ancestry by predicted genetic ancestry with a 718 probability > 90% provided by AoU yielding 48,112 individuals in the AoU. For variant quality 719 control beyond AoU central efforts, we further filtered SNPs to include MAF > 0.001 which 720 retained 12,416,130 SNPs. We performed a similar guality control for imputed genotype data 721 for South Asian ancestry in the Genes & Health cohort with additional criteria of INFO score 722 > 0.6 and genotype missing rate < 5%. Individuals with a missing rate > 5% were removed. 723 Eventually, 44,396 individuals and 8,935,207 SNPs remained in Genes & Health.

725 Assessment of clinical utility

726

724

727 We applied PRSmix and PRSmix+ for coronary artery disease as a clinical application. The 728 phenotypic algorithm includes at least one ICD or CPT code below: ICD9 410x, 411x, 412x; 729 ICD10 I22x, I23x, I24.1, I25.2 CPT 92920-92979 (PCI), 33533-33536, 33517-33523, 33510-730 33516 (CABG) or self-reported personal history of MI or CAD. CAD in Genes and Health 731 cohort was defined with at least one ICD10 I22x, I23x, I24.1, I25 or operation codes K401, 732 K402, K403, K404, K411, K451, K452, K453, K454, K455, K491, K492, K499, K502, K751, 733 K752, K753, K754, K758, K759 or SNOMED codes 1755008, 22298006, 54329005, 734 57054005, 65547006, 70211005, 70422006, 73795002, 233838001, 304914007. 735 401303003, 401314000.

736

The category-free NRI was used to evaluate the clinical utility. NRI was calculated by adding the PRS to the baseline logistic model including age, sex, the first 10 principal components, and clinical risk factors. The clinical risk factors include total cholesterol, HDL-C, BMI, type 2 diabetes, and current smoking status or model includes only age, sex, and 10 principal components. NRI was calculated as the sum of NRI for cases and NRI for controls:

742

$$NRI = P(up|case) - P(down|case) + P(down|control) - P(up|control)$$

743

P(up|case) and P(down|case) estimate the proportion of cases that had higher or lower risk after classification with logistic regression, respectively. The confidence interval for NRI was estimated with 500 bootstraps. We also compared the risk increase between individuals in the top decile of PRS versus those remaining in the population. In addition to liability R² to compare the PRS performance, we also used the incremental area under the curve (AUC) to compare the PRS. The incremental AUC was estimated as the difference between the AUC of models with the integrative score versus the model with only clinical variables.

- 752 wMT-SBLUP and linear combination of LDpred2-auto derived scores
- 753

754 LDpred2-auto: LDpred2 is a Bayesian method that computes the adjusted SNP effect sizes 755 from GWAS summary statistics. LDpred2 utilizes the SNP effect sizes as prior and 756 incorporates LD between markers to infer the posterior effect sizes. In our work, we 757 implemented LDpred2-auto⁵¹ since this method can infer heritability and the proportion of causal variants. LDpred2-auto was conducted with 800 burn-in iterations and 500 iterations. 758 759 The proportion of causal variants was initialized between 10⁻⁴ and 0.9. Furthermore, 760 LDpred2-auto does not require a validation set, the SNP effect sizes were averaged 761 between scores. We used 1,138,726 HapMap3 variants that overlapped with SNPs from 762 whole-genome sequencing data in the All of Us cohort. The LD reference panel developed 763 from European ancestry was provided by the LDpred2-tutorial.

764

wMT-SBLUP: wMT-SBLUP¹⁹ calculates the mixing weights of PRS using sample sizes from 765 766 GWAS summary statistics, SNP-heritability and genetic correlation. We compared wMT-767 SBLUP with our method using 5 traits that were originally assessed with wMT-SBLUP 768 including CAD, T2D, depression, height, and BMI. We curated 26 publicly available GWAS 769 summary statistics (Supplementary Table 18) and performed LDpred2-auto with quality 770 controls suggested by Privé et al^{5,51}. We used LD score regression to estimate SNP-771 heritability and genetic correlation across 26 traits. For each of the 5 outcome traits, we 772 selected correlated traits with P-value of genetic correlation less than 0.05.

773

Elastic Net for linear combination: we also implemented linear combination by Elastic Net
 with the LDpred2-auto-derived PRSs for contributing traits since this strategy was proposed
 by several works^{8,13,20}. We selected scores with significant variance explained (P value<0.05) to the outcome trait and conducted Elastic Net using the *glmnet* R package⁴⁶.

778

779 Phenome-wide association study

780

781 We obtained the list of 1815 phecodes from the PheWAS website (last accessed December 782 2022)⁵². The phecodes were based on ICD-9 and ICD-10 to classify individuals. PheWAS 783 was conducted on European ancestry only in AoU. For each phecodes as the outcome, we 784 conducted an association analysis using logistic regression on PRS and adjusted for age, 785 sex, and first 10 PCs. The significance threshold for PheWAS was estimated as 2.75 x 10⁻⁵ 786 (0.05/1815) after Bonferroni correction.

787

788 Data availability

789

The PGS Catalog is freely available at <u>https://www.pgscatalog.org/</u>. Our new scores are deposited in the PGS Catalog. The All of Us and Genes & Health individual-level data is a controlled access dataset and may be granted at <u>https://www.researchallofus.org/</u> and <u>https://www.genesandhealth.org/</u>, respectively.

794

The weights from the PRSmix and PRSmix+ scores in this manuscript have been returned to
the PGS Catalog. The R package to implement PRSmix and PRSmix+ in independent
datasets is at https://github.com/buutrg/PRSmix.

798

799 Software/analyses:

Analyses were performed on the AoU Researcher Workbench in Jupyter Notebook 14 using
R version 4.0.0 programming language. Results are reported in compliance with the AoU
Data and Statistics Dissemination Policy.

803

804 ACKNOWLEDGEMENT

805

We would like to thank Alkes L. Price for critical comments for this works. L.E.H. is supported by the National Human Genome Research Institute (K08HG012221). P.N. is supported by grants from NHGRI (U01HG011719), NHLBI (R01HL142711, R01HL127564, R01HL151152), and Massachusetts General Hospital (Paul & Phyllis Fireman Endowed Chair in Vascular Medicine). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

812

813 The All of Us Research Program is supported by the National Institutes of Health, Office of 814 the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 815 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 816 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally 817 Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C 818 OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant 819 Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 820 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 821 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research 822 Program would not be possible without the partnership of its participants.

823

824 Genes & Health is/has recently been core-funded by Wellcome (WT102627, WT210561), 825 the Medical Research Council (UK) (M009017), Higher Education Funding Council for 826 England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London 827 substantive site), and research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames). Genes & Health is/has recently been 828 829 funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life Sciences Industry 830 Consortium of Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development 831 Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, 832 Takeda Development Centre Americas Inc.

833

834 We thank Social Action for Health, Centre of The Cell, members of our Community Advisory 835 Group, and staff who have recruited and collected data from volunteers. We thank the NIHR 836 National Biosample Centre (UK Biocentre), the Social Genetic & Developmental Psychiatry 837 Centre (King's College London), Wellcome Sanger Institute, and Broad Institute for sample 838 processing, genotyping, sequencing and variant annotation. We thank: Barts Health NHS 839 Trust, NHS Clinical Commissioning Groups (City and Hackney, Waltham Forest, Tower 840 Hamlets, Newham, Redbridge, Havering, Barking and Dagenham), East London NHS 841 Foundation Trust, Bradford Teaching Hospitals NHS Foundation Trust, Public Health 842 England (especially David Wyllie), Discovery Data Service/Endeavour Health Charitable 843 Trust (especially David Stables), NHS Digital - for GDPR-compliant data sharing backed by 844 individual written informed consent.

845

846 Most of all we thank all of the volunteers participating in the All of Us Research Program and

847 Genes & Health.

848 849 **CONFLICT OF INTEREST**

850

851 P.N. reports grants from Allelica, Amgen, Apple, Boston Scientific, Genentech, and Novartis, 852 is a consultant to Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, 853 HeartFlow, Novartis, Genentech, and GV, scientific advisory board membership to Esperion 854 Therapeutics, Preciseli, and TenSixteen Bio, is a scientific co-founder of TenSixteen Bio, 855 and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. 856 Others declare no conflict of interest.

857 **REFERENCES**

- 1. Catalog, P. G. S. PGS Catalog the Polygenic Score Catalog.
- 859 http://www.pgscatalog.org/.
- 2. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk
- 861 score analyses. *Nat. Protoc.* **15**, 2759–2772 (2020).
- 3. Dudbridge, F. Power and predictive accuracy of polygenic risk scores. *PLoS Genet.* **9**,
- e1003348 (2013).
- 4. Choi, S. W. & O'Reilly, P. SA20 PRSice 2: POLYGENIC RISK SCORE SOFTWARE
- 865 (UPDATED) AND ITS APPLICATION TO CROSS-TRAIT ANALYSES. Eur.
- 866 *Neuropsychopharmacol.* **29**, S832 (2019).
- 5. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. *Bioinformatics*
- 868 (2020) doi:10.1093/bioinformatics/btaa1029.
- 869 6. Vilhjálmsson, B. J. et al. Modeling Linkage Disequilibrium Increases Accuracy of

870 Polygenic Risk Scores. Am. J. Hum. Genet. 97, 576–592 (2015).

- 7. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via
- Bayesian regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).
- 873 8. Abraham, G. et al. Genomic risk score offers predictive performance comparable to
- clinical risk factors for ischaemic stroke. *Nat. Commun.* **10**, 5819 (2019).
- 9. Chung, W. et al. Efficient cross-trait penalized regression increases prediction accuracy
- in large cohorts using secondary phenotypes. *Nat. Commun.* **10**, 569 (2019).
- 10. Weissbrod, O. et al. Leveraging fine-mapping and multipopulation training data to
- improve cross-population polygenic risk scores. *Nat. Genet.* **54**, 450–458 (2022).
- 11. Inouye, M. et al. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults:
- 880 Implications for Primary Prevention. J. Am. Coll. Cardiol. 72, 1883–1893 (2018).
- 12. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat.*
- 882 *Genet.* **54**, 573–580 (2022).
- 13. Albiñana, C. et al. Multi-PGS enhances polygenic prediction: weighting 937 polygenic
- scores. Preprint at https://doi.org/10.1101/2022.09.14.22279940.

23

- 14. Watanabe, K. et al. A global overview of pleiotropy and genetic architecture in complex
- 886 traits. *Nat. Genet.* **51**, 1339–1348 (2019).
- 15. Li, C., Yang, C., Gelernter, J. & Zhao, H. Improving genetic risk prediction by leveraging
 pleiotropy. *Hum. Genet.* 133, 639–650 (2014).
- 16. Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health
- disparities. *Nature Genetics* vol. 51 584–591 Preprint at https://doi.org/10.1038/s41588-
- 891 019-0379-x (2019).
- 17. Lambert, S. A. *et al.* The Polygenic Score Catalog as an open database for
- reproducibility and systematic evaluation. *Nat. Genet.* **53**, 420–425 (2021).
- 18. Buch, G., Schulz, A., Schmidtmann, I., Strauch, K. & Wild, P. S. A systematic review
- and evaluation of statistical methods for group variable selection. *Stat. Med.* **42**, 331–
- 896 352 (2023).
- Maier, R. M. *et al.* Improving genetic prediction by leveraging genetic correlations
 among human diseases and traits. *Nat. Commun.* 9, (2018).
- 899 20. Krapohl, E. *et al.* Multi-polygenic score approach to trait prediction. *Mol. Psychiatry* 23,
 900 1368–1374 (2018).
- 901 21. Yengo, L. *et al.* A saturated map of common genetic variants associated with human
 902 height. *Nature* 610, 704–712 (2022).
- 22. Klarin, D. & Natarajan, P. Clinical utility of polygenic risk scores for coronary artery
 disease. *Nat. Rev. Cardiol.* 19, 291–301 (2022).
- 905 23. Heart Association Council on Epidemiology, A. Heart disease and stroke statistics-
- 906 2022 update: a report from the American Heart Association. *Circulation* (2022).
- 907 24. Arnett, D. K. et al. 2019 ACC/AHA Guideline on the Primary Prevention of
- 908 Cardiovascular Disease: A Report of the American College of Cardiology/American
- 909 Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 140, e596–
 910 e646 (2019).
- 911 25. Koyama, S. et al. Population-specific and trans-ancestry genome-wide analyses identify
- 912 distinct and shared genetic risk loci for coronary artery disease. Nat. Genet. 52, 1169–

- 913 1177 (2020).
- 914 26. Tamlander, M. et al. Integration of questionnaire-based risk factors improves polygenic
- 915 risk scores for human coronary heart disease and type 2 diabetes. Commun Biol 5, 158
- 916 (2022).
- 917 27. Zhang, H. et al. Novel methods for multi-ancestry polygenic prediction and their
- 918 evaluations in 5.1 million individuals of diverse ancestry. *bioRxiv* (2022)
- 919 doi:10.1101/2022.03.24.485519.
- 920 28. Sud, M. et al. Population-Based Recalibration of the Framingham Risk Score and
- 921 Pooled Cohort Equations. J. Am. Coll. Cardiol. 80, 1330–1342 (2022).
- 922 29. Carroll, R. J., Bastarache, L. & Denny, J. C. R PheWAS: data analysis and plotting tools
- 923 for phenome-wide association studies in the R environment. *Bioinformatics* **30**, 2375–
- 924 2376 (2014).
- 30. Bastarache, L., Denny, J. C. & Roden, D. M. Phenome-Wide Association Studies. *JAMA*327, 75–76 (2022).
- 927 31. Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. *J. R. Stat.*
- 928 Soc. Series B Stat. Methodol. 67, 301–320 (2005).
- 929 32. Zhou, D.-X. On grouping effect of elastic net. Stat. Probab. Lett. 83, 2108–2112 (2013).
- 930 33. Zou, H. & Hastie, T. Addendum: Regularization and variable selection via the elastic
- 931 net. J. R. Stat. Soc. Series B Stat. Methodol. 67, 768–768 (2005).
- 932 34. Wang, M. et al. Validation of a Genome-Wide Polygenic Score for Coronary Artery
- 933 Disease in South Asians. J. Am. Coll. Cardiol. 76, 703–714 (2020).
- 35. Lloyd-Jones, L. R. *et al.* Improved polygenic prediction by Bayesian multiple regression
- 935 on summary statistics. *Nat. Commun.* **10**, 5086 (2019).
- 936 36. Wang, Y., Tsuo, K., Kanai, M., Neale, B. M. & Martin, A. R. Challenges and
- 937 opportunities for developing more generalizable polygenic risk scores. Annu. Rev.
- 938 Biomed. Data Sci. 5, 293–320 (2022).
- 939 37. Mostafavi, H. et al. Variable prediction accuracy of polygenic scores within an ancestry
- 940 group. *Elife* **9**, (2020).

- 941 38. Mapes, B. M. et al. Diversity and inclusion for the All of Us research program: A scoping
- 942 review. PLoS One 15, e0234962 (2020).
- 943 39. The "All of Us" Research Program. N. Engl. J. Med. 381, 668–676 (2019).
- 944 40. Cronin, R. M. et al. Development of the initial surveys for the All of Us Research
- 945 Program. Epidemiology 30, 597-608 (2019).
- 946 41. All of Us Research Program Protocol. All of Us Research Program | NIH
- 947 https://allofus.nih.gov/about/all-us-research-program-protocol (2020).
- 948 42. Pereira, F. Home. Terra.Bio https://terra.bio/ (2020).
- 949 43. Researcher Workbench. https://www.researchallofus.org/workbench/.
- 950 44. Data Methods – All of Us Research Hub. https://www.researchallofus.org/data-
- 951 tools/methods.
- 952 45. Finer, S. et al. Cohort Profile: East London Genes & Health (ELGH), a community-
- 953 based population genomics and health study in British Bangladeshi and British Pakistani
- 954 people. International Journal of Epidemiology vol. 49 20-21i Preprint at
- 955 https://doi.org/10.1093/ije/dyz174 (2020).
- 956 46. Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear
- 957 models via coordinate descent. J. Stat. Softw. 33, 1-22 (2010).
- 958 47. Lee, S. H., Clark, S. & van der Werf, J. H. J. Estimation of genomic prediction accuracy
- 959 from reference populations with varying degrees of relationship. PLoS One 12,
- 960 e0189775 (2017).
- 961 48. Wishart, J., Kondo, T. & Elderton, E. M. The mean and second moment coefficient of 962 the multiple correlation coefficient, in samples from a normal population. Biometrika 22, 963
- 353 (1931).
- 964 49. Stuart, A., Ord, K. & Arnold, S. Kendall's Advanced Theory of Statistics, Classical 965 Inference and the Linear Model. (Wiley, 2010).
- 966 50. Momin, M. M., Lee, S., Wray, N. R. & Lee, S. H. Significance tests for R2 of out-of-
- 967 sample prediction using polygenic scores. Am. J. Hum. Genet. (2023)
- 968 doi:10.1016/j.ajhg.2023.01.004.

- 969 51. Privé, F., Arbel, J., Aschard, H. & Vilhjálmsson, B. J. Identifying and correcting for
- 970 misspecifications in GWAS summary statistics and polygenic scores. HGG Adv. 3,
- 971 100136 (2022).
- 972 52. Denny, J. C. et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to
- 973 discover gene-disease associations. *Bioinformatics* **26**, 1205–1210 (2010).
- 974